» Articles » PMID: 32170961

Combined Use of Cytology, P16 Immunostaining and Genotyping for Triage of Women Positive for High-risk Human Papillomavirus at Primary Screening

Overview
Journal Int J Cancer
Specialty Oncology
Date 2020 Mar 15
PMID 32170961
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Human papillomavirus (HPV) testing is very sensitive for primary cervical screening but has low specificity. Triage tests that improve specificity but maintain high sensitivity are needed. Women enrolled in the experimental arm of Phase 2 of the New Technologies for Cervical Cancer randomized controlled cervical screening trial were tested for high-risk HPV (hrHPV) and referred to colposcopy if positive. hrHPV-positive women also had HPV genotyping (by polymerase chain reaction with GP5+/GP6+ primers and reverse line blotting), immunostaining for p16 overexpression and cytology. We computed sensitivity, specificity and positive predictive value (PPV) for different combinations of tests and determined potential hierarchical ordering of triage tests. A number of 1,091 HPV-positive women had valid tests for cytology, p16 and genotyping. Ninety-two of them had cervical intraepithelial neoplasia grade 2+ (CIN2+) histology and 40 of them had CIN grade 3+ (CIN3+) histology. The PPV for CIN2+ was >10% in hrHPV-positive women with positive high-grade squamous intraepithelial lesion (61.3%), positive low-grade squamous intraepithelial lesion (LSIL+) (18.3%) and positive atypical squamous cells of undetermined significance (14.8%) cytology, p16 positive (16.7%) and, hierarchically, for infections by HPV33, 16, 35, 59, 31 and 52 (in decreasing order). Referral of women positive for either p16 or LSIL+ cytology had 97.8% sensitivity for CIN2+ and women negative for both of these had a 3-year CIN3+ risk of 0.2%. Similar results were seen for women being either p16 or HPV16/33 positive. hrHPV-positive women who were negative for p16 and cytology (LSIL threshold) had a very low CIN3+ rate in the following 3 years. Recalling them after that interval and referring those positive for either test to immediate colposcopy seem to be an efficient triage strategy. The same applies to p16 and HPV16.

Citing Articles

Extended HPV genotyping by the BD Onclarity assay: concordance with screening HPV-DNA assays, triage biomarkers, and histopathology in women from the NTCC2 study.

De Marco L, Bisanzi S, Ronco G, Mancuso P, Carozzi F, Allia E Microbiol Spectr. 2024; 13(1):e0089724.

PMID: 39576120 PMC: 11723576. DOI: 10.1128/spectrum.00897-24.


Clinically validated HPV assays offer comparable long-term safety in primary cervical cancer screening: A 9-year follow-up of a population-based screening cohort.

Ostrbenk Valencak A, Kroon K, Fabjan D, Mlakar J, Seme K, Berkhof J Int J Cancer. 2024; 156(4):788-801.

PMID: 39315642 PMC: 11661515. DOI: 10.1002/ijc.35200.


Structured Literature Review to Identify Human Papillomavirus's Natural History Parameters for Dynamic Population Models of Vaccine Impacts.

Diakite I, Martins B, Owusu-Edusei K, Palmer C, Patterson-Lomba O, Gomez-Lievano A Infect Dis Ther. 2024; 13(5):965-990.

PMID: 38589763 PMC: 11098984. DOI: 10.1007/s40121-024-00952-z.


Associations of multi-human papillomavirus infections with expression of p16 in a cohort of women who underwent colposcopy: a retrospective study of 5165 patients.

Zhang Y, Li H, Li X, Li Z, You Q, Liu H Front Oncol. 2023; 13:1265726.

PMID: 37965476 PMC: 10641385. DOI: 10.3389/fonc.2023.1265726.


Validation of an on-chip p16/Ki-67 dual immunostaining cervical cytology system using microfluidic device technology.

Hashimoto K, Kumagai T, Nomura K, Miyagawa Y, Tago S, Takasaki K Sci Rep. 2023; 13(1):17052.

PMID: 37816765 PMC: 10564753. DOI: 10.1038/s41598-023-44273-6.